Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway
Author:
Funder
Hubei University of Medicine
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s00280-021-04363-6.pdf
Reference33 articles.
1. Sadykova LR, Ntekim AI, Muyangwa-Semenova M, Rutland CS, Jeyapalan JN, Blatt N, Rizvanov AA (2020) Epidemiology and risk factors of osteosarcoma. Cancer Invest 38:259–269
2. Yu D, Zhang S, Feng A, Xu D, Zhu Q, Mao Y, Zhao Y, Lv Y, Han C, Liu R, Tian Y (2019) Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: a meta-analysis and clinical observation. Medicine (Baltimore). https://doi.org/10.1097/MD.0000000000015582
3. Kager L, Tamamyan G, Bielack S (2017) Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol 13:357–368
4. Jafari F, Javdansirat S, Sanaie S, Naseri A, Shamekh A, Rostamzadeh D, Dolati S (2020) Osteosarcoma: a comprehensive review of management and treatment strategies. Ann Diagn Pathol. https://doi.org/10.1016/j.anndiagpath.2020.151654
5. Kitajima S, Li F, Takahashi C (2020) Tumor milieu controlled by RB tumor suppressor. Int J Mol Sci. https://doi.org/10.3390/ijms21072450
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09
2. Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?;Cancers;2023-10-19
3. Osteosarcoma Multi-Omics Landscape and Subtypes;Cancers;2023-10-13
4. The Targeted Therapies for Osteosarcoma via Six Major Pathways;Current Molecular Pharmacology;2023-10-11
5. Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation;Frontiers in Pharmacology;2023-05-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3